The emergence of coronavirus disease 2019 (COVID-19) has created new challenges in the management of serious diseases. We describe a 41-year-old male who presented with fever, watery diarrhea, and epistaxis. Initial workup revealed pancytopenia with >50% blasts on the peripheral smear raising suspicion of acute myeloid leukemia (AML) (later confirmed by bone marrow biopsy as AML with myelodysplasia-related changes) and a positive polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the extraordinary risk, he was treated with remdesivir and convalescent plasma for COVID-19. On admission day 8, repeat PCR for SARS-CoV-2 returned negative and the patient was deemed stable for chemotherapy. Therefore, induction was done with liposomal daunorubicin and cytarabine. However, he did not respond to the therapy and was started on re-induction therapy with decitabine and venetoclax. In our discussion, we review the current principles of treatment of patients with concurrent COVID-19 and AML.
【저자키워드】 Remdesivir, corona virus disease 2019, COVID 19, Convalescent plasma therapy, novel corona virus, acute myeloblastic leukemia, acute myeloid leukemia (aml), 【초록키워드】 COVID-19, Treatment, coronavirus disease, convalescent plasma, SARS-CoV-2, coronavirus, therapy, Diseases, risk, diarrhea, Bone marrow, Chemotherapy, PCR, management, Fever, male, Patient, Admission, leukemia, AML, peripheral smear, changes, acute respiratory syndrome, venetoclax, positive, polymerase chain, the patient, treated, respond, returned, watery, was done, raising, 【제목키워드】 challenge, myeloid, concurrent,